[Cutaneous side effects of EGF receptor inhibitors]

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Epidermal Growth Factor Receptor (EGFR) inhibitors are a class of targeted therapy drugs.
• These inhibitors are utilized in the treatment of various solid tumors.
• Cutaneous toxicity is a common and specific side effect associated with EGFR inhibitor therapy.

Purpose of the Study:

• To provide a comprehensive overview of the cutaneous manifestations resulting from EGFR inhibitor use.
• To discuss the management strategies for managing skin toxicity induced by EGFR inhibitors.

Main Methods:

• Literature review of studies on EGFR inhibitors and their dermatological side effects.
• Synthesis of information on clinical presentation and treatment protocols for cutaneous toxicities.

Main Results:

• Cutaneous side effects are frequently observed in patients treated with EGFR inhibitors.
• The severity and type of skin toxicity can vary.
• There is a correlation between the occurrence of skin toxicity and the antitumoral efficacy of EGFR inhibitors.

Conclusions:

• Understanding the spectrum of cutaneous manifestations is crucial for patient management.
• Effective management of skin toxicity can improve patient compliance and treatment outcomes.
• The link between skin toxicity and therapeutic effect highlights the importance of monitoring and supportive care.